In 2 trials, less toxic TB antibiotics show promise
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000 The newly published results of two small clinical trials suggest that two novel antibiotics could provide safer alternatives to a highly toxic antibiotic currently used in drug-resistant tuberculosis (DR-TB) treatment regimens. The phase 2 trials evaluated the efficacy, safety, and optimal dosing of sutezolid and delpazolid when used in combination with bedaquiline, delamanid, and moxifloxacin. Both drugs are from the same class of antibiotic
